Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.54 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA7 | P43166 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13469243 | 0.87 | CYP46A1 (0.51) | CYP46A1NR4A2TDP1MAPTNPSR1 | |
| SCHEMBL12858187 | 0.86 | CYP46A1 (0.50) | CYP46A1NR4A2TDP1MAPTNPSR1 | |
| SCHEMBL14533454 | 0.84 | TSHR (0.52) | TDP1MAPTGAAL3MBTL1KMT2A | |
| SCHEMBL6246970 | 0.84 | CYP46A1 (0.49) | CYP46A1NR4A2TDP1MAPTNPSR1 | |
| SCHEMBL10633837 | 0.82 | CA12 (0.62) | MAPTGAAKMT2AHPGDCA12 | |
| SCHEMBL5251510 | 0.82 | KDM4E (0.54) | TDP1MAPTHTTGAAKMT2A | |
| SCHEMBL29059212 | 0.81 | NPSR1 (0.50) | CYP46A1NR4A2TDP1MAPTNPSR1 | |
| SCHEMBL2772400 | 0.81 | CYP46A1 (0.50) | CYP46A1NR4A2TDP1MAPTNPSR1 | |
| SCHEMBL7335943 | 0.81 | CYP46A1 (0.47) | CYP46A1NR4A2TDP1MAPTNPSR1 | |
| SCHEMBL7662781 | 0.81 | NR4A2 (0.49) | NR4A2MAPTHTTGAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1891019-B1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMA INC (US) | 2012-07-25 | — | — | EP | disclosed |
| US-7879890-B2 | hydantoin derivatives that can inhibit matrix metalloproteinases and tumor necrosis factor alpha-converting enzyme, to prevent the release of tumor necrosis factor; treatment of septic shock, reperfusion injuries, meningitis, psoriasis, arthritis, inflammatory bowel disease and ankylosing spondylitis | SCHERING CORPORATION (US) | 2011-02-01 | — | — | US | disclosed |
| US-7687527-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2010-03-30 | — | — | US | disclosed |
| US-20090170875-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION | 2009-07-02 | — | — | US | disclosed |
| US-20090137586-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION | 2009-05-28 | — | — | US | disclosed |
| US-7504424-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-03-17 | — | — | US | disclosed |
| US-7488745-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-02-10 | — | — | US | disclosed |
| US-20070219218-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2007-09-20 | — | — | US | disclosed |
| US-20060276506-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219218-A1 | Compounds for the treatment of inflammatory disorders | ADAMTS1, ADAMTS13, ADAMTS7 | CYP46A1 203/4885NR4A2 2786/4885TDP1 1779/4885 |
| US-20090170875-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | ADAMTS1, ADAMTS13, ADAMTS7 | CYP46A1 203/4885NR4A2 2786/4885TDP1 1779/4885 |
| US-20090137586-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | ADAMTS1, ADAMTS13, ADAMTS7 | CYP46A1 203/4885NR4A2 2786/4885TDP1 1779/4885 |
| US-20060276506-A1 | Compounds for the treatment of inflammatory disorders | ADAMTS1, ADAMTS13, ADAMTS7 | CYP46A1 203/4885NR4A2 2786/4885TDP1 1779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.